Pfizer-BioNTech’s COVID-19 vaccine gets slightly weaker over time

The vaccine had a sky-high efficacy rate of about 96 per cent against symptomatic COVID-19 for the first two months, but then declined about 6 per cent every two months after that, a study showed.